UroGen Pharma Ltd. financial data

Symbol
URGN on Nasdaq
Location
Ra'anana, Israel
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 02 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 443% % -41%
Quick Ratio 22% % -1.9%
Debt-to-equity -333% % -102%
Return On Equity 170% %
Return On Assets -73% % -54%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48,682,280 shares 5.6%
Common Stock, Shares, Outstanding 48,350,272 shares 14%
Entity Public Float $620,400,000 USD -8.1%
Common Stock, Value, Issued $133,000 USD 16%
Weighted Average Number of Shares Outstanding, Basic 48,116,098 shares 2.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $109,788,000 USD 21%
Cost of Revenue $12,447,000 USD 40%
Research and Development Expense $67,107,000 USD 17%
Operating Income (Loss) $124,863,000 USD -29%
Nonoperating Income (Expense) $670,000 USD -193%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $153,416,000 USD -24%
Income Tax Expense (Benefit) $78,000 USD -97%
Net Income (Loss) Attributable to Parent $153,494,000 USD -21%
Earnings Per Share, Basic -3.19 USD/shares -6.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $110,745,000 USD -36%
Cash, Cash Equivalents, and Short-term Investments $120,500,000 USD -50%
Accounts Receivable, after Allowance for Credit Loss, Current $33,082,000 USD 63%
Inventory, Net $16,464,000 USD 78%
Assets, Current $186,024,000 USD -33%
Property, Plant and Equipment, Net $637,000 USD -2.7%
Operating Lease, Right-of-Use Asset $3,080,000 USD 263%
Other Assets, Noncurrent $5,161,000 USD 776%
Assets $200,455,000 USD -30%
Accounts Payable, Current $12,137,000 USD 11%
Employee-related Liabilities, Current $13,516,000 USD 28%
Liabilities, Current $46,418,000 USD 1%
Operating Lease, Liability, Noncurrent $2,646,000 USD 4462%
Liabilities $305,929,000 USD 3.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax $19,000 USD -66%
Retained Earnings (Accumulated Deficit) $959,716,000 USD -19%
Stockholders' Equity Attributable to Parent $105,474,000 USD -1098%
Liabilities and Equity $200,455,000 USD -30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $42,024,000 USD -32%
Net Cash Provided by (Used in) Financing Activities $54,657,000 USD 8046%
Net Cash Provided by (Used in) Investing Activities $25,963,000 USD -292%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 48,350,272 shares 14%
Common Stock, Par or Stated Value Per Share 0.01 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $67,953,000 USD -286%
Deferred Tax Assets, Valuation Allowance $198,448,000 USD 18%
Deferred Tax Assets, Gross $200,402,000 USD 18%
Operating Lease, Liability $3,127,000 USD 121%
Payments to Acquire Property, Plant, and Equipment $44,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $153,531,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid $4,078,000 USD 165%
Property, Plant and Equipment, Gross $5,224,000 USD 5.8%
Operating Lease, Liability, Current $481,000 USD -39%
Lessee, Operating Lease, Liability, to be Paid, Year Two $960,000 USD 1555%
Lessee, Operating Lease, Liability, to be Paid, Year One $818,000 USD -0.49%
Operating Lease, Weighted Average Discount Rate, Percent 0.1181 pure 15%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $951,000 USD 680%
Lessee, Operating Lease, Liability, to be Paid, Year Three $878,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $153,354,000 USD 25%
Unrecognized Tax Benefits $1,807,000 USD -8.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four $603,000 USD
Operating Lease, Payments $220,000 USD -21%
Depreciation, Depletion and Amortization $307,000 USD -6.7%
Deferred Tax Assets, Net of Valuation Allowance $1,954,000 USD 154%
Share-based Payment Arrangement, Expense $11,959,000 USD -8.8%